|By Marketwired .||
|February 3, 2014 06:00 AM EST||
FOSTER CITY, CA -- (Marketwired) -- 02/03/14 -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Friedhelm Blobel, Ph.D., Chief Executive Officer, will present a corporate overview and business update at the 16th Annual BIO CEO & Investor Conference at 10:00 am ET on Tuesday, February 11, 2014, at the Waldorf Astoria Hotel in New York City.
To access the live audio webcast of these presentations, please log on through a link located in the Investor Relations section of SciClone's website at www.sciclone.com, under the Calendar of Events tab. A replay of the webcast will be available one hour after the conclusion of the live events.
SciClone Pharmaceuticals is a revenue-generating, specialty pharmaceutical company with a substantial commercial business in China and a product portfolio spanning major therapeutic markets, including oncology, infectious diseases and cardiovascular disorders. SciClone's proprietary lead product, ZADAXIN® (thymalfasin), is approved in over 30 countries and may be used for the treatment of hepatitis B (HBV), hepatitis C (HCV), and certain cancers, and as a vaccine adjuvant, according to the local regulatory approvals. Through its promotion business with pharmaceutical partners, SciClone markets multiple branded products in China which are therapeutically differentiated. The Company has successfully in-licensed products with the potential to become future market leaders and to drive the Company's long-term growth. SciClone is a publicly-held corporation based in Foster City, California, and trades on the NASDAQ Global Select Market under the symbol SCLN. For additional information, please visit www.sciclone.com.
This press release contains forward-looking statements regarding expected financial results and expectations. Readers are urged to consider statements that include the words "may," "will," "would," "could," "should," "might," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," "unaudited," "approximately" or the negative of those words or other comparable words to be uncertain and forward-looking. These statements are subject to risks and uncertainties that are difficult to predict and actual outcomes may differ materially. Please also refer to other risks and uncertainties described in SciClone's filings with the SEC. All forward-looking statements are based on information currently available to SciClone and SciClone assumes no obligation to update any such forward-looking statements.
SciClone, SciClone Pharmaceuticals, the SciClone Pharmaceuticals design, the SciClone logo and ZADAXIN are registered trademarks of SciClone Pharmaceuticals, Inc. in the United States and numerous other countries.
Without a clear strategy for cost control and an architecture designed with cloud services in mind, costs and operational performance can quickly get out of control. To avoid multiple architectural redesigns requires extensive thought and planning. Boundary (now part of BMC) launched a new public-facing multi-tenant high resolution monitoring service on Amazon AWS two years ago, facing challenges and learning best practices in the early days of the new service. In his session at 19th Cloud Exp...
Dec. 2, 2016 05:15 PM EST Reads: 312
Dec. 2, 2016 05:00 PM EST Reads: 4,059
Dec. 2, 2016 04:45 PM EST Reads: 2,088
Dec. 2, 2016 04:45 PM EST Reads: 1,954
Dec. 2, 2016 04:15 PM EST Reads: 316
Dec. 2, 2016 04:15 PM EST Reads: 287
Dec. 2, 2016 04:01 PM EST Reads: 234
Dec. 2, 2016 04:00 PM EST Reads: 1,855
Dec. 2, 2016 03:45 PM EST Reads: 629
Dec. 2, 2016 03:30 PM EST Reads: 3,183
Dec. 2, 2016 03:15 PM EST Reads: 1,440
Dec. 2, 2016 02:15 PM EST Reads: 1,510
Dec. 2, 2016 02:00 PM EST Reads: 4,818
Dec. 2, 2016 01:30 PM EST Reads: 5,692
Dec. 2, 2016 01:30 PM EST Reads: 1,805